drugset / Trial / NCT02976740

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

NCT02976740

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the treatment of stage IV NSCLC patients who failed in second-line chemotherapy.

Timeline

Start
2016-11
Primary completion
2019-06
Completion
2019-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymalfasin Peptide 1.6 mg Subcutaneous
Subject human recombined granulocyte-macrophage colony stimulating factor Unknown 125 ug/m2 Subcutaneous

Indications